News & Events about Zymeworks Inc.
Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that management will participate in the following upcoming investor conferences: Guggenheim Oncology Conference 2023. Zymeworks management will participate in...
Jazz Pharmaceuticals and Zymeworks Announce 84% Overall Survival at 18 Months from Phase 2 Trial Evaluating Zanidatamab in HER2-Expressing Metastatic Gastroesophageal Adenocarcinoma Jazz Pharmaceuticals and Zymeworks Announce 84% Overall Survival at 18 Months from Phase 2 Trial Evaluating...
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Q3 2022 Earnings Call Transcript November 9, 2022 Jazz Pharmaceuticals plc beats earnings expectations. Reported EPS is $5.17, expectations were $4.66. Operator: Good day, and thank you for standing by. Welcome to the Q3 2022 Jazz Pharmaceuticals Earnings Call...
Zymeworks will receive $350 million from Jazz Pharmaceuticals in return for the right to develop and commercialize Zymeworks lead drug candidate, zanidatamab, in the U.S., Europe and Japan. The new cash builds on a $50 million payment earlier this year and comes after Tuesdays release of positive ...
Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that management will participate in an upcoming investor conference: JP Morgan Healthcare Conference. Zymeworks management will participate in one-on-one meetings...